Abstract
Aim: To evaluate efficacy of continuous treatment for subacute variant of EAA with inhalation lasolvan.
Materials and methods: We studied 27 patients with subacute course of morphologically confirmed EAA. Group 1 (10 patients) received the standard treatment with prednisolone (20 mg/day). Group 2 (17 patients) received prednisolone (15 mg/day) plus inhalation lasolvan. We evaluated clinical symptoms (cumulative index), 6-minute walk test, spirometry, diffusing capacity of the lung (DLCO), computed tomography (CT) of the lungs using Kazerooni modification, before and after the treatment. The reliability of differences was estimated using the Wilcocson test.
Results: There were no reliable differences between the groups. The analysis of the data within the both groups revealed reliable improvement of clinical symptoms, LVC, distances of the 6-minute walk test, the alveolar component of CT. In group 2 we also observed increased DLCO.
Conclusion: Nebulizer administration of lasolvan in the complex treatment for subacute course of EAA allows decreasing corticosteroid doses.
- © 2012 ERS